Skip to main content
Fig. 1 | BMC Microbiology

Fig. 1

From: Bifidobacterium longum SX-1326 ameliorates gastrointestinal toxicity after irinotecan chemotherapy via modulating the P53 signaling pathway and brain-gut axis

Fig. 1

Schematic of whole experimental schedule and construction of a mouse model of CRC. A Processing schedule to explain experimental design of animal experiments; B Monitoring colorectal neoplasia and H&E staining tumor tissue; C Weekly body weight change of mice in each group. Experimental group: M: colorectal cancer model group; B: Bifidobacterium longum SX-1326 group; I: Irinotecan chemotherapy group; U: Bifidobacterium longum SX-1326 plus irinotecan dosing group.Data are expressed as mean ± SD, *p < 0.05, **p < 0.01

Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us